

Unravelling CACNA1A Channelopathies: CRISPR and iPSC Models for Rapid Functional Analysis of Genetic Variants

O. Kayden Wright^{1,2}, Catherine Forbes¹, Paula Gomez^{1,2}, Katy Morris¹, Maxine Smith¹, Linda K Wijaya¹, Nicole Shaw¹, Michelle Ward³, Cathryn Poulton^{4,5}, Gareth Baynam^{3,4}, Timo Lassman^{1,2}, Vanessa S Fear^{1,2}


¹Translational Genetics Team, The Kids Research Institute Australia, Nedlands, ²School of Biomedical Sciences, University of Western Australia, Crawley, ³Western Australian Register of Developmental Anomalies, King Edward Memorial Hospital, Subiaco, Western Australia, Australia. ⁴Undiagnosed Diseases Program, Genetic Health, Subiaco, Western Australia, Australia. ⁵Genetic Health of WA, King Edward Memorial Hospital, Subiaco, Western Australia, Australia

BACKGROUND


- CACNA1A encodes the $\alpha 1A$ subunit of $Ca_v2.1$ voltage gated calcium channels.¹
- $Ca_v2.1$ channels are key modulators of fast synaptic transmission in excitatory and inhibitory neurons in the CNS.¹
- CACNA1A related channelopathies are associated with a spectrum of disease including hemiplegic migraine, episodic ataxia, epilepsy, intellectual disability.¹
- Two patients were identified with VUS in CACNA1A:
 - NM_001127221.2:c.4312_4314del; p.(Lys1438del)
 - NM_001127221.2:c.5876C>A; p.(Ala1959Asp)
- Aims: 1. Generate iPSC lines harbouring patient VUSs
2. Differentiate iPSC to NPCs for future functional analysis.



METHOD



RESULTS



ID	VUS	Phenotype
VUS1	p.Lys1438del	Ataxia, brain atrophy, nystagmus
VUS2	p.Ala1959Asp	Seizures, migraine, episodic ataxia

Neural differentiation of CACNA1A VUS and WT iPSC lines




Figure 3. A and B. Cellular morphology of matched VUS and WT cells at days 0 and 19 of neural induction. Scale bar = 100 μ m. C and D. Percentage of CACNA1A p.Lys1438del (C) and CACNA1A p.Ala1959Asp (D) cells positive for marker expression at days 0 and 19 of neural induction. Ordinary 2-way ANOVA, $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), $p < 0.0001$ (****) day 0 to day 19. No significant difference between WT and VUS.

CRISPR-Cas9 gene editing to introduce CACNA1A genetic variants




Figure 2. A. HDR percentage from polyclonal post-transfection populations for each crRNA designed. B. Amplicon sequencing of selected CACNA1A p.Lys1438del clones. C. Amplicon sequencing of selected CACNA1A p.Ala1959Asp clones. D. Quality control analysis. Karyotyping qPCR and amplicon sequencing of top six CRISPR off-target sites. Analysis performed on individual clonal populations.

Preliminary immunohistochemistry of iPSC derived NPCs and mature neurons




Figure 5. A. Expression of CACNA1A, PAX6, DCX, and TUBB3 in CACNA1A p.Lys1438del VUS and WT NPCs at day 19 of neural induction. B. Expression of TUBB3, Synapsin, MAP2, NeuN, FOXG1, and GFAP in WT neurons at 21 days of maturation. Scale bar = 50 μ m.

CONCLUSION

- Matched WT and VUS iPSC lines were established for each patient VUS.
- iPSC lines were differentiated to NPCs. Preliminary immunofluorescence indicates limited expression of CACNA1A.
- Preliminary immunofluorescence indicates successful maturation of neurons via BrainPhys™ hPSC Neuron Kit.
- Matched VUS and WT NPCs to be matured via BrainPhys™ hPSC neuron kit ahead of functional assessment of variant effect by calcium flux imaging and functional transcriptomic profiling.

